Hepatic Disease in Patients With HIV
Summary
- Improving systemic insulin resistance may be beneficial but is not sufficient to prevent progression of fatty liver disease
- US and European guidelines support reserving the use of pharmacotherapy for treatment of insulin resistance to patients with NASH or fibrosis[AASLD NAFLD; EASL NAFLD]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content